Adagene (ADAG) Stock Price, News & Analysis

Company Overview

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key Stats

• Today's Range: $2.15 to $2.30
• 50-Day Range: $1.65 to $2.39
• 52-Week Range: $1.33 to $3.58
• Volume: 44,535 shs
• Average Volume: 111,887 shs
• Market Capitalization: $104.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Adagene Stock Analysis - MarketRank™

Adagene scored higher than 60% of companies evaluated by MarketBeat, and ranked 427th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adagene has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adagene are expected to decrease in the coming year, from ($0.60) to ($0.76) per share.

Price to Book Value per Share Ratio

Adagene has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Adagene has been sold short.

Short Interest Ratio / Days to Cover

Adagene has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adagene has recently decreased by 6.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adagene does not currently pay a dividend.

Dividend Growth

Adagene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of Adagene has been sold short.

Short Interest Ratio / Days to Cover

Adagene has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adagene has recently decreased by 6.55%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.92

News Sentiment

Adagene has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Adagene this week, compared to 1 article on an average week.

Search Interest

3 people have searched for ADAG on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adagene insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.51% of the stock of Adagene is held by institutions.

ADAG Stock Analysis - Frequently Asked Questions

How have ADAG shares performed this year?

Adagene's stock was trading at $1.99 at the beginning of the year. Since then, ADAG shares have increased by 11.6% and is now trading at $2.22.

When did Adagene IPO?

Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager.

Who are Adagene's major shareholders?

Top institutional investors of Adagene include Marex Group plc (0.05%).

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adagene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Today: 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADAG
• CIK: 1818838
• Web: www.adagene.com
• Phone: 86-512-8777-3632
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adagene: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +215.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.29
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 1,045.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.80 per share
• Price / Book: 2.78

Miscellaneous

• Outstanding Shares: 47,110,000
• Free Float: 37,123,000
• Market Cap: $104.58 million
• Optionable: Not Optionable
• Beta: 0.74